153 related articles for article (PubMed ID: 29371477)
1. Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors.
Nishijima TF; Deal AM; Williams GR; Sanoff HK; Nyrop KA; Muss HB
Oncologist; 2018 May; 23(5):573-579. PubMed ID: 29371477
[TBL] [Abstract][Full Text] [Related]
2. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.
Moth EB; Kiely BE; Stefanic N; Naganathan V; Martin A; Grimison P; Stockler MR; Beale P; Blinman P
J Geriatr Oncol; 2019 Mar; 10(2):202-209. PubMed ID: 30224184
[TBL] [Abstract][Full Text] [Related]
3. Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers.
Nishijima TF; Deal AM; Williams GR; Sanoff HK; Nyrop KA; Muss HB
Cancer; 2022 May; 128(10):1929-1936. PubMed ID: 35147991
[TBL] [Abstract][Full Text] [Related]
4. Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol.
Steinmeyer Z; Gérard S; Filleron T; Lozano S; Brechemier D; Abellan Van Kan G; Mourey L; Cristol-Dalstein L; De Decker L; Rolland Y; Balardy L
BMC Cancer; 2019 Nov; 19(1):1153. PubMed ID: 31775667
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
6. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
Hurria A; Togawa K; Mohile SG; Owusu C; Klepin HD; Gross CP; Lichtman SM; Gajra A; Bhatia S; Katheria V; Klapper S; Hansen K; Ramani R; Lachs M; Wong FL; Tew WP
J Clin Oncol; 2011 Sep; 29(25):3457-65. PubMed ID: 21810685
[TBL] [Abstract][Full Text] [Related]
7. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study.
Ostwal V; Ramaswamy A; Bhargava P; Hatkhambkar T; Swami R; Rastogi S; Mandavkar S; Ghosh J; Bajpai J; Gulia S; Srinivas S; Rath S; Gupta S
BMJ Open; 2021 Jun; 11(6):e047376. PubMed ID: 34187825
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
10. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Younes A; Fayad L; Rodriguez MA; Hagemeister FB; Barista I; Cabanillas F; Cox JD
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):36-43. PubMed ID: 12504034
[TBL] [Abstract][Full Text] [Related]
11. Prediction of hospital admissions and grade 3-4 toxicities in cancer patients 70 years old and older receiving chemotherapy.
Reed M; Patrick C; Quevillon T; Walde N; Voutsadakis IA
Eur J Cancer Care (Engl); 2019 Nov; 28(6):e13144. PubMed ID: 31429128
[TBL] [Abstract][Full Text] [Related]
12. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
14. Utility of a chemotherapy toxicity prediction tool for older patients in a community setting.
Mariano C; Jamal R; Bains P; Hejazi S; Chao L; Wan J; Ho J
Curr Oncol; 2019 Aug; 26(4):234-239. PubMed ID: 31548802
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
16. Use of palliative chemotherapy in patients aged 80 years and over with incurable cancer: experience at three Sydney cancer centres.
Ip E; Pokorny AM; Della-Fiorentina S; Beale P; Bray V; Kiely BE; Blinman P
Intern Med J; 2017 Jan; 47(1):75-81. PubMed ID: 27749003
[TBL] [Abstract][Full Text] [Related]
17. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
18. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
19. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
20. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
